Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
about
From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsLessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Metastatic pancreatic neuroendocrine tumor with ectopic adrenocorticotropic hormone production.Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT studyHyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis.Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesDirect cytosolic delivery of polar cargo to cells by spontaneous membrane-translocating peptides.Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors.Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature.Two patients with a neuroendocrine tumour of the small intestine and paraneoplastic myasthenia gravis.Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors.Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours.CT and enhanced CT in diagnosis of gastrointestinal neuroendocrine carcinomas.
P2860
Q26822011-251E2F6E-3F19-4889-B045-03A9134C1152Q34173001-44CCCE99-4EB3-4940-B2B5-5111279FD895Q34689054-B86CEAA0-AD98-4BF0-93CF-6A888D0B7570Q35120723-D692DB8A-2070-4111-ACD6-0E96339AD7F2Q35768274-5096DFF4-6402-4339-BBEA-1A9CFC5B4979Q36739229-A21CC512-E68C-4536-B527-E068B4A3D4B7Q37125550-8A2BCC0C-5DBB-447F-81C5-3D66D787DBFCQ37226280-DFF1DC89-5B2E-48B0-9129-846BE5C7B96EQ37246135-9D464784-5188-4CF4-B4F3-24C866B87DE0Q37980202-F42664C0-46CF-4634-B3F5-BBB427814847Q38027524-B040024D-2211-430B-9A86-24D18BD491D0Q39669438-542615F7-4EFB-4EB0-A326-B17473750586Q40453835-0602C073-D56E-4584-A714-F80AAD701EFDQ43803622-F96BEACE-D7AA-4CB6-A808-2F94BD947827Q50136080-E2E11497-A840-410F-B226-9D5EAA0FAFF8Q50969115-4E6FC23E-A215-46AF-AF1F-9CB4A031C9E4
P2860
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Biological targeted therapies ...... tic neuroendocrine carcinomas.
@en
Biological targeted therapies ...... tic neuroendocrine carcinomas.
@nl
type
label
Biological targeted therapies ...... tic neuroendocrine carcinomas.
@en
Biological targeted therapies ...... tic neuroendocrine carcinomas.
@nl
prefLabel
Biological targeted therapies ...... tic neuroendocrine carcinomas.
@en
Biological targeted therapies ...... tic neuroendocrine carcinomas.
@nl
P2093
P1476
Biological targeted therapies ...... tic neuroendocrine carcinomas.
@en
P2093
Evaristo Maiello
Francesca Spada
Gianfranco Delle Fave
Giovanni Paganelli
Katia Lorizzo
Laura Orlando
Lisa Bodei
Michela Squadroni
Nicola Fazio
Saverio Cinieri
P304
P356
10.1016/S0305-7372(10)70026-8
P478
36 Suppl 3
P577
2010-11-01T00:00:00Z